Vesalius et al. invest €4m in Pluriomics

The company plans to use the fresh funding to strengthen its research and development, as well as bolster its commercial team in Leiden. It is in the process of setting up a production facility in Gosselies in the Walloon region of Belgium.

Pluriomics will also use the capital to further develop and begin commercialisation of its stem-cell-derived cardiomyocytes and assays.

IQ is the regional development agency for South Holland.

Company
Founded in 2010 and headquartered in Leiden, Pluriomics has developed its Pluricyte cardiomyocytes, which are human cardiac muscle cells designed for use in drug discovery.

The Pluricyte assays are designed to detect potentially toxic side-effects of new medicines that are in early development.

The company's products are designed to improve accuracy in early medicine testing and provide an alternative to animal testing.

People
Herman Spolders is the CEO of Pluriomics; he founded the company alongside chief scientific officer Stefan Braam. Alain Parthoens is a managing partner at Vesalius. Philippe Degive is an investment manager at SRIW, while Gerty Holla is an investment manager at IQ.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Early-stage
• Healthcare
• Netherlands